Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, posted on LinkedIn:
”Great result
I was really pleased to hear from Brian O’Mahony that the World Health Organisation (WHO) has listened and changed its lists of core and complementary products to treat diseases when it comes to haemophilia. Their previous, (still the current), list suggests cryoprecipitate as a core treatment for haemophilia, which is strange as it has poor efficacy and is not safe in the countries likely to use it. Congratulations to the World Federation of Hemophilia for all their hard work representing the haemophilia community and persuading the WHO to implement this change.
The new recommendations appearing on the next edition of the lists will now show:
a) Removal of pathogen-reduced cryoprecipitate and cryoprecipitate from the core list
b) Plasma-derived FVIII and FIX will be moved from the complimentary to the core list
c) Prothrombin complex concentrate (PCC) for the treatment of haemophilia B will be removed from the list due to the thrombotic risk
d) Recombinant FVIII and FIX will now be on the core list for prophylaxis and on-demand treatment
e) Emicizumab will be added to the complimentary list for prophylaxis in haemophilia A for persons with and without inhibitors.
Two key lessons:
1. When the haemophilia community works together, it achieves results
2. The WHO should rely on experts who are directly involved in the treatment of a specific disease.”
Stay updated with Hemostasis Today.
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 06:22Noa Kabera Joins EAHAD as Project Coordinator to Advance Haemophilia and Allied Disorders Care
-
Sep 8, 2025, 03:48Blood Podcast Alert: Voxelotor Drops, Pediatric SCD, Thrombosis in VEXAS Syndrome and TKIs in ALL
-
Sep 7, 2025, 16:14Paddy Barret on Thin Cap Fibroatheroma's Outcomes
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 7, 2025, 14:11New RPTH Journal Research: Statins Reduce Thrombosis Risk but Not Severity of Pulmonary Embolism
-
Sep 7, 2025, 13:37Unfractionated Heparin Dosing in ECMO: A Systematic Review and Meta-Analysis
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress
-
Sep 8, 2025, 05:27Kerry Bozza Funkhouser at BIC 2025 Roundtable on Heavy Menstrual Bleeding and Rare Bleeding Disorders